Analytical Data
-
Gene name
SST
- Application
-
Alternative Names
SST；Somatostatin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P61278
-
Expression Region
89-116aa
-
AA Sequence
SA NSNPAMAPRE RKAGCKNFFW KTFTSC
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of SST (Somatostatin) recombinant proteins has gained significant attention due to their critical role in various physiological processes, including the regulation of endocrine functions and neurotransmission. Somatostatin is a peptide hormone that inhibits the secretion of several other hormones, thereby playing a vital role in maintaining homeostasis within the body. Recombinant technology allows for the production of SST in a more controlled and efficient manner, enabling researchers to explore its therapeutic potential in treating conditions such as acromegaly, neuroendocrine tumors, and gastrointestinal disorders. Furthermore, the development of SST analogs has been instrumental in enhancing stability and specificity, leading to improved pharmacological profiles. As researchers continue to elucidate the structure-function relationships of SST and its receptors through recombinant protein studies, there is growing potential for innovative treatment strategies that leverage these insights to address unmet medical needs. This research not only helps deepen our understanding of somatostatin's biological functions but also opens avenues for biotechnological applications in drug development and targeted therapies.
